Sign Up Today and Learn More About AIBioTech Stock

Invest in or calculate the value of your shares in AIBioTech or other pre-IPO companies through EquityZen's platform.

Get Started

AIBioTech Stock

Contract research organization

About AIBioTech Stock

Founded

1992

Headquarters

Richmond, VA, US

AIBioTech provides drug discovery and diagnostic development organizations a broad range of world-class laboratory services to bring new products to market. Located in a 32,000 square foot laboratory in Richmond, Virginia, AIBioTech is one of the world's most comprehensive Contract Research Organizations in operation. AIBioTech provides reliable expertise and cutting-edge technologies which are not available from other companies. An expert core laboratory, we provide consultation on experimental design and offer comprehensive services under GLP and non-GLP compliance. These services are offered individually or can be integrated to support product development from discovery-to-market with full Regulatory Support under FDA GLP Guidelines 21 CFR 58. AIBioTech provides the following capabilities to clients: Molecular biology Protein expression & analysis and peptide synthesis & purification Bio-analytical services (CLIA certified) Assay development and validation Microbiology, virology & biosafety testing (BSL3 facilities) Program expertise

AIBioTech Management

Leadership team at AIBioTech

Executive VP

Thomas R. Reynolds

Director of Biological Chemistries

Russell L. Wolz

Locked Features

Join now and verify your accreditation status to gain access to:

  • AIBioTech current valuation
  • AIBioTech stock price
  • Available deals in AIBioTech and all other companies
  • Deal offering documents
  • EquityZen's proprietary data and insights, including
    • Cap tables, which include funding history by Share Class and Liquidity Preferences
    • Company Highlights
    • Business Model
    • Risk Factors
Join Now

How to invest in AIBioTech stock?

Accredited investors can buy pre-IPO stock in companies like AIBioTech through EquityZen funds. These investments are made available by existing AIBioTech shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process here.

How to sell AIBioTech stock?

Shareholders can sell their AIBioTech stock through EquityZen's private company marketplace. EquityZen's network includes over 310K accredited investors interested in buying private company stock. Learn more about the easy and guided Shareholder process here.

If I invest, how do I exit my investment?

There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. More information on Express Deals can be found here and exit information can be found here.

Why choose EquityZen?

Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 41K private placements completed across 450+ companies, EquityZen leads the way in delivering "Private Markets for the Public."